Our results show that out of the 390 patients diagnosed with non-mucinous ovarian cancer, the high-grade serous ovarian cancer subtype, 300 had a negative result, 48 had a pathogenic BRCA1 mutation, 24 had a pathogenic BRCA2 mutation, two had a mutation in the BRCA1 gene with uncertain significance, six had a mutation in the BRCA2 gene with an uncertain significance VUS (variant with uncertain significance), five had the moderate risk variant c.9976A>T (p.Lys3326Ter) in the BRCA2 gene, and five had a large deletion in the BRCA1 gene (Table 1). This evidence concerns the gene BRCA2 and mucinous ovarian cancer.